Neurological Diseases: Drugs
The question
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle shortages of medicine for people with (a) epilepsy and (b) Parkinson’s disease.
Answered by Karin Smyth
The Department is working hard with industry to help resolve intermittent supply issues with some epilepsy medications. As a result of ongoing activity and intensive work, including directing suppliers to expedite deliveries, most issues, including with carbamazepine, lamotrigine, and oxcarbazepine presentations, have been resolved.
We are currently aware of an ongoing supply issue with all strengths of topiramate tablets from one manufacturer. This supply issue is expected to resolve by the end of May 2025. We are also aware of a shortage of phenobarbital 15 milligram tablets from one manufacturer, with the resupply date to be confirmed. In both cases, alternative suppliers are in stock with sufficient supply to support patients, and these issues have been communicated to the National Health Service.
The Department is aware of supply constraints with one supplier of amantadine 100 milligram capsules used in the management of Parkinson’s Disease, however stocks remain available from alternative suppliers to cover demand. The Department has also been notified of a discontinuation of apomorphine (APO-go PFS) 50 milligram/10millilitre pre-filled syringes from April 2025. Alternative formulations of apomorphine remain available for patients, and management guidance has been issued to the NHS.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →